MICHAEL P. BAILEY - 20 Dec 2022 Form 4 Insider Report for AVEO PHARMACEUTICALS, INC.

Role
President & CEO, Director
Signature
/s/ Danielle V. Holland, attorney in fact
Issuer symbol
N/A
Transactions as of
20 Dec 2022
Net transactions value
+$1,248,144
Form type
4
Filing time
22 Dec 2022, 15:46:26 UTC
Previous filing
17 Feb 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVEO Common Stock Options Exercise $164,294 +26,499 +47% $6.20 82,920 20 Dec 2022 Direct F1
transaction AVEO Common Stock Options Exercise $480,043 +85,722 +95% $5.60 175,642 20 Dec 2022 Direct
transaction AVEO Common Stock Options Exercise $603,807 +164,525 +94% $3.67 340,167 20 Dec 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVEO Stock Option (right to buy) Options Exercise $0 -26,499 -22% $0.000000 93,500 20 Dec 2022 Common Stock 26,499 $6.20 Direct F2
transaction AVEO Stock Option (right to buy) Options Exercise $0 -85,722 -71% $0.000000 35,302 20 Dec 2022 Common Stock 85,722 $5.60 Direct F3
transaction AVEO Stock Option (right to buy) Options Exercise $0 -164,525 -21% $0.000000 625,192 20 Dec 2022 Common Stock 164,525 $3.67 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,110 shares purchased by the Reporting Person under the Company's 2010 Employee Stock Purchase Plan, as amended.
F2 The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company.
F3 The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company.
F4 The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company.